10-May-2024
Cantor picks 14 undervalued biotech stocks worth a second look
Seeking Alpha News (Sun, 12-May 11:00 AM ET)
REGENXBIO to Participate in Upcoming Investor Conferences
PRNewswire (Fri, 10-May 7:05 AM ET)
Buy Rating Affirmed for RegenXBio on Clinical Progress and Promising Therapeutic Candidates
TipRanks (Fri, 10-May 1:43 AM ET)
Buy Rating Affirmed for RegenXBio Amid Promising Drug Developments and Solid Financials
TipRanks (Fri, 10-May 1:29 AM ET)
HHS panel to vote in Nov. on DMD screening for newborns
Seeking Alpha News (Thu, 9-May 6:44 PM ET)
RBC Capital Sticks to Its Buy Rating for RegenXBio (RGNX)
TipRanks (Thu, 9-May 6:54 AM ET)
RegenXBio (RGNX) Receives a Buy from Barclays
TipRanks (Thu, 9-May 3:26 AM ET)
Regenxbio GAAP EPS of -$1.38 misses by $0.11, revenue of $15.62M misses by $7.9M
Seeking Alpha News (Wed, 8-May 4:51 PM ET)
REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights
PRNewswire (Wed, 8-May 4:05 PM ET)
PRNewswire (Wed, 1-May 7:05 AM ET)
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Regenxbio trades on the NASDAQ stock market under the symbol RGNX.
As of May 10, 2024, RGNX stock price declined to $15.44 with 401,489 million shares trading.
RGNX has a beta of 1.63, meaning it tends to be more sensitive to market movements. RGNX has a correlation of 0.12 to the broad based SPY ETF.
RGNX has a market cap of $760.51 million. This is considered a Small Cap stock.
Last quarter Regenxbio reported $16 million in Revenue and -$1.38 earnings per share. This fell short of revenue expectation by $-8 million and missed earnings estimates by -$.12.
In the last 3 years, RGNX stock traded as high as $46.46 and as low as $11.83.
The top ETF exchange traded funds that RGNX belongs to (by Net Assets): IJR, VTI, VB, XBI, IWM.
RGNX has underperformed the market in the last year with a price return of -19.8% while the SPY ETF gained +27.8%. RGNX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -4.8% and -4.6%, respectively, while the SPY returned +4.2% and +2.5%, respectively.
RGNX support price is $15.05 and resistance is $16.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RGNX stock will trade within this expected range on the day.